cancer-nursing-2019-posters-abstracts

allied

academies

Page 41

April 15-16, 2019 | Frankfurt, Germany

Oncology Nursing and Cancer Care

International Conference on

Journal of Medical Oncology and Therapeutics | Volume 4

Neoadjuvant chemotherapy for male with locally advanced breast cancer

Murashko R, Keshabyan A

and

Zandaryan A

Regional Cancer Centre, Russia

Introduction:

Male breast cancers (MBC) are rare

cancers that include less than 1% of all breast

cancers and less than 1% of all cancers in men.

Unfortunately, at the moment there is no single

view on the problem of breast cancer treatment.

The principles of treatment of breast cancer in men

are still based on knowledge, including in relation

to women with a similar pathology. Neoadjuvant

chemotherapy is a standard aid for local breast

cancer in women. Our study was designed to

evaluate the potential for surgery on the chest (BS)

after neoadjuvant chemotherapy inmenwith locally

advanced breast cancer and the selection of the

optimal adjuvant chemotherapy regimen.

Patients andmethods:

We performed retrospective

analysis of short-term outcomes of ten breast

cancer patients. All patients were male median

age 50.2 years luminal biological subtype of tumor.

Three patients had stage IIB (T2N1М0) and seven

patients had stage IIIA (Т3N1М0) were selected to

3 cycles taxane-based neoadjuvant chemotherapy.

One patient who had a positive luminal biological

subtype of HER-2 tumor, was added Trastuzumab

to the treatment regimen. Adjuvant chemotherapy,

radiotherapy and hormonal treatment were given

to all patients.

Results:

All patients underwent surgical treatment.

Response to chemotherapy was the only statistically

significant factorwhich influences theBS. All patients

showed positive changes in the form of a reduction

in the size of the tumor, and the same decrease in

the size of the axillary lymph nodes.

Conclusion:

We recommend all patients (men)

with locally advanced breast cancer to perform

neoadjuvant chemotherapy; this will allow you to

choose the optimal mode of adjuvant therapy.

adrianudrea@medisprof.ro